Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026
Rhea-AI Summary
Incannex Healthcare (Nasdaq: IXHL) has received a final A$5,102,788.30 refund under the Australian Government’s R&D Tax Incentive Program, following approval of its overseas findings and amendment of its FY25 income tax return.
Combined with the previously announced A$6,039,162.43 refund, Incannex has now secured more than A$11.2 million in non-dilutive capital during 2026. According to the company, the proceeds, received without issuing equity or taking on debt, further strengthen its cash position and debt-free balance sheet, support advancement of key clinical assets such as IHL-42X and PSX-001, and align with its shareholder-focused capital allocation strategy. Incannex also expects additional R&D tax funding in 2027 for eligible ongoing activities.
Positive
- A$5.1 million final FY25 R&D tax refund received in 2026
- Total FY25 R&D Tax Incentive proceeds exceed A$11.2 million
- All R&D tax proceeds are non-dilutive, with no new equity or debt
- Company reports a debt-free balance sheet and strong cash position
- Non-dilutive capital supports clinical assets including IHL-42X and PSX-001
- Company expects additional R&D Tax Incentive funding in 2027
Negative
- None.
News Explained
In the latest supplied quarter ended
Sources and calculations
- Latest quarterly fundamentals (2026Q3)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $74,450,000 / ($2,456,000 / 90) = [object Object]
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 23 | Phase 2 study screening | Positive | +1.3% | Participant screening began for the DReAMzz Phase 2 IHL-42X study. |
| Jun 25 | Patent grant | Positive | -1.5% | U.S. patent protection for IHL-42X was granted through July 2040. |
| Jun 10 | R&D tax refund | Positive | +6.5% | Incannex received A$6,039,162.43 under the Australian R&D Tax Incentive Program. |
| Jun 09 | Research coverage | Positive | +7.9% | Alliance Global Partners initiated equity research coverage on Incannex. |
| May 14 | Phase 2 study launch | Positive | +0.8% | The DReAMzz clinical study of IHL-42X officially commenced. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive announcements were usually aligned with gains, although the June 25 patent announcement diverged with a decline.
Key Terms
r&d tax incentive program financial
non-dilutive capital financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Completion of more than A
NEW YORK and MELBOURNE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative combination therapies and psychedelic-assisted treatments, today announced it has received the final A
Together with the previously announced A
Highlights
- Received the final A
$5.1 million R&D Tax Incentive refund following approval of overseas findings, further strengthening the Company’s balance sheet with non-dilutive capital. Incannex expects to receive additional R&D Tax Incentive funding in 2027 in respect of eligible ongoing research and development activities. - The refund recognizes the significant eligible Australian research and development activities undertaken by the Company in developing therapeutic regimens designed to address challenging chronic conditions during the financial year ended 30 June 2025.
- Total FY25 R&D Tax Incentive proceeds now exceed A
$11.2 million - Entire amount received as non-dilutive capital, with no shareholder dilution
- Further strengthens the Company’s already robust balance sheet and financial flexibility
- Supports continued advancement of key clinical assets, including IHL-42X and PSX-001
- Reinforces disciplined capital management and shareholder-focused capital allocation strategy
The Australian Government’s Research and Development Tax Incentive Program is designed to encourage innovation by providing eligible companies with cash refunds for qualifying research and development activities.
Following approval of the Company’s overseas findings, Incannex amended its FY25 income tax return, resulting in the additional refund announced today. This outcome reflects the Company’s successful execution of its strategy to maximize eligible R&D incentives while continuing to invest in the advancement of its clinical pipeline.
Importantly, these proceeds are entirely non-dilutive, enabling Incannex to recover a substantial portion of eligible research and development expenditure without issuing additional equity or taking on debt. At a time when many biotechnology companies continue to rely on dilutive capital raises to fund operations, the Company believes this outcome further differentiates the strength of its financial position and disciplined approach to capital management.
Joel Latham, President and Chief Executive Officer of Incannex Healthcare, commented:
“The receipt of this final refund completes more than A
“Combined with our existing cash position and debt-free balance sheet, this additional capital further enhances our financial flexibility as we continue advancing our late-stage clinical pipeline, including IHL-42X and PSX-001, while maintaining a strong focus on shareholder returns.
“We believe the market continues to significantly undervalue the strength of our balance sheet relative to our enterprise value. The completion of more than A
About Incannex Healthcare Inc.
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing innovative combination therapies and next-generation medicines for conditions with significant unmet medical need. The Company’s lead programs include IHL-42X for obstructive sleep apnea, IHL-675A for rheumatoid arthritis and PSX-001 for generalized anxiety disorder. Incannex is committed to advancing therapies that address multiple biological pathways with the goal of improving patient outcomes and creating long-term shareholder value. For more information, please visit www.incannex.com.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to management’s expectations regarding the development, regulatory progress and commercialization of the Company’s drug candidates, the potential value of the Company’s drug candidates and business, and potential shareholder value. When or if used in this communication, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to the Company, its operations or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management’s current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the risk that the Company’s estimates and current projections regarding the sufficiency of its current cash on hand to fund the Company’s planned operations may be incorrect and the Company may use these resources faster than anticipated, risks associated with the clinical development of IHL-42X and PSX-001, and other risks described in the section entitled “Risk Factors” described in the Company’s annual report on Form 10-K for the fiscal year ended June 30, 2025, filed with the SEC on September 29, 2025, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, which can be obtained on the SEC website at www.sec.gov and are made available on the Company’s website upon their filing with the SEC. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
Investor & Media Contacts
CORE IR
(212) 655-0924
investors@incannex.com
media@incannex.com.au
